RUBICONRubicon Research Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why buy
- • Revenue growth: 43.5% YoY
- • Profit growth: 96.6% YoY
- • ROE: 27.0%
- • RSI: 60
- • Price vs EMA21: above
- • Price vs SMA50: above
- • Pullback to 21-EMA signal (setup quality 72%)
Bull case
- • Revenue growth: 43.5% YoY
- • Profit growth: 96.6% YoY
- • ROE: 27.0%
- • RSI: 60
Bear case
- • Valuation vs sector: P/E 120.8 vs sector 40.5
- • Dividend yield: 0.00%
- • MACD: bearish
- • Volume: 0.7x 20-day average
Key risks
- • Valuation vs sector: P/E 120.8 vs sector 40.5
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹74.86). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.